EMEA-002350-PIP01-18-M03 - paediatric investigation plan
Deucravacitinib
PIPHuman
Key facts
- Invented name
- Sotyktu
- Active Substance
- Deucravacitinib
- Therapeutic area
- Skin and subcutaneous tissue disorders
- Decision number
- P/0008/2024
- PIP number
- EMEA-002350-PIP01-18-M03
- Pharmaceutical form(s)
- Film-coated tablet
- Age-appropriate oral solid dosage form
- Condition(s) / indication(s)
- Treatment of psoriasis
- Route(s) of administration
- Oral use
- Contact for public enquiries
Bristol-Myers Squibb Pharma EEIG
E-mail: medical.information@bms.com
Tel. +44 (0)1423 533610- Decision type
- PM: decision on the application for modification of an agreed PIP
- Decision date